DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

Information source: LEO Pharma
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Venous Thromboembolism

Phase: N/A

Status: Completed

Sponsored by: LEO Pharma

Official(s) and/or principal investigator(s):
Dominique Farge Bancel, Pr, Principal Investigator, Affiliation: Groupe Francophone Thrombose et Cancer

Summary

The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism. This study also aims at gathering epidemiological data on the Low Molecular Weight Heparin therapy of Venous Thromboembolism in patients with cancer.

Clinical Details

Official title: Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Prescription conditions and use of Low Molecular Weight Heparin in the French usual practice for the treatment of symptomatic Venous Thromboembolism in patients with cancer at up to 6 months

Secondary outcome:

To evaluate the consistency of the Low Molecular Weight Heparin use with French national recommendations on the treatment of Venous Thromboembolism in patients with cancer.

To evaluate Venous Thromboembolism recurrences, bleeding, thrombocytopenia and deaths during Low Molecular Weight Heparin treatment

To describe clinical factors associated with treatment duration with Low Molecular Weight Heparin and those associated with the occurrence of Venous Thromboembolism in patients with cancer

To evaluate the anticoagulant treatment perception and satisfaction by patients with cancer disease with a validated questionnaire

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects must provide informed consent

- Men or women aged 18 years or more

- Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low

Molecular Weight Heparin before entry into the study Exclusion Criteria:

- Contraindication to the use of Low Molecular Weight Heparin

Locations and Contacts

Hopital Saint Louis, Paris 75010, France
Additional Information

Starting date: November 2012
Last updated: September 18, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017